VarmX, a biotech company focused on developing innovative approaches for reversing anticoagulation, has announced that it will be attending the LSX World Congress on April 29-30 and presenting at Bio€quity Europe on May 12-14. The LSX World Congress is a prominent partnering, strategy, and investment event in Europe that features 1:1 partnering opportunities. VarmX will be attending to engage with investors and other biopharmaceutical companies. Martijn Negen, VarmX’s SVP Global Commercial Strategy & Business Development, will participate in a panel discussion at the event.
Bio€quity Europe, organized by BioCentury, is a key biopartnering event for the European biotech industry. Martijn Negen has been selected to present at this prestigious event. If you wish to meet with the VarmX Team at either of these upcoming events or obtain more information, please contact: info@varmx.com.
VarmX is a spin-off from the Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, an expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X developed for treating severe spontaneous bleeding and preventing bleeding during urgent surgeries in patients using oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is backed by a strong group of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, and InnovationQuarter.
For media inquiries, please contact Instinctif Partners at Melanie Toyne-Sewell / Katie Duffell Tel: +44 20 7457 2020 Email: VarmX@instinctif.com.